by Vandana Singh | Oct 1, 2026 | General
Eli Lilly and Co. (NYSE:LLY) on Thursday announced post-hoc analyses from its ATTAIN-1 study alongside detailed Phase 3 ACHIEVE-4 trial results.The findings demonstrate that Foundayo (orforglipron) significantly lowers predicted risks for type 2 diabetes and...
by Surbhi Jain | Oct 1, 2026 | General
Micron Technology, Inc. (NASDAQ:MU) has reached a point where the value of memory its customers have already committed to buy is larger than everything the company sold in its entire latest financial year. The chipmaker said Sept. 30 that it now has about $150 billion...
by Anusuya Lahiri | Oct 1, 2026 | General
Semiconductor companies are capturing a growing share of the artificial intelligence investment boom. Hyperscaler spending, tight memory supply and demand for advanced manufacturing, packaging and custom silicon are lifting valuations across the chip industry.Several...
by Benzinga Insights | Oct 1, 2026 | General
Agilent Technologies (NYSE:A) has outperformed the market over the past 15 years by 1.05% on an annualized basis producing an average annual return of 14.43%. Currently, Agilent Technologies has a market capitalization of $48.21 billion. Buying $1000 In A: If an...
by Vandana Singh | Oct 1, 2026 | General
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) reported Phase 1 trial results for its inflammatory disease drug candidate MRT-8102, while outlining plans to advance the treatment into multiple Phase 2 studies. The biotechnology firm announced that its NEK7-directed...
Recent Comments